| MeSH term | MeSH ID | Detail |
|---|---|---|
| Synovitis, Pigmented Villonodular | D013586 | 1 associated lipids |
| Periostitis | D010522 | 1 associated lipids |
| Prosthesis Failure | D011475 | 1 associated lipids |
| Adrenal Hyperplasia, Congenital | D000312 | 2 associated lipids |
| Angina, Stable | D060050 | 2 associated lipids |
| Sarcoma, Ewing | D012512 | 2 associated lipids |
| Tooth Mobility | D014086 | 2 associated lipids |
| Urologic Neoplasms | D014571 | 2 associated lipids |
| Microvascular Angina | D017566 | 2 associated lipids |
| Otosclerosis | D010040 | 2 associated lipids |
7-octadecynoic acid
7-octadecynoic acid is a lipid of Fatty Acyls (FA) class.
Cross Reference
There are no associated biomedical information in the current reference collection.
Current reference collection contains 19785 references associated with 7-octadecynoic acid in LipidPedia. Due to lack of full text of references or no associated biomedical terms are recognized in our current text-mining method, we cannot extract any biomedical terms related to diseases, pathways, locations, functions, genes, lipids, and animal models from the associated reference collection.
Users can download the reference list at the bottom of this page and read the reference manually to find out biomedical information.
Here are additional resources we collected from PubChem and MeSH for 7-octadecynoic acid
Possible diseases from mapped MeSH terms on references
We collected disease MeSH terms mapped to the references associated with 7-octadecynoic acid
All references with 7-octadecynoic acid
Download all related citations| Authors | Title | Published | Journal | PubMed Link |
|---|---|---|---|---|
| Sangai T et al. | Roles of osteoclasts and bone-derived IGFs in the survival and growth of human breast cancer cells in human adult bone implanted into nonobese diabetic/severe combined immunodeficient mice. | 2008 | Clin. Exp. Metastasis | pmid:18307047 |
| Zheng Y et al. | Bone resorption increases tumour growth in a mouse model of osteosclerotic breast cancer metastasis. | 2008 | Clin. Exp. Metastasis | pmid:18421566 |
| Kiefer JA et al. | The effect of osteoprotegerin administration on the intra-tibial growth of the osteoblastic LuCaP 23.1 prostate cancer xenograft. | 2004 | Clin. Exp. Metastasis | pmid:15672862 |
| Tannehill-Gregg SH et al. | The effect of zoledronic acid and osteoprotegerin on growth of human lung cancer in the tibias of nude mice. | 2006 | Clin. Exp. Metastasis | pmid:16715352 |
| Ainola M et al. | Imbalanced expression of RANKL and osteoprotegerin mRNA in pannus tissue of rheumatoid arthritis. | 2008 Mar-Apr | Clin. Exp. Rheumatol. | pmid:18565244 |
| Kwan Tat S et al. | The differential expression of osteoprotegerin (OPG) and receptor activator of nuclear factor kappaB ligand (RANKL) in human osteoarthritic subchondral bone osteoblasts is an indicator of the metabolic state of these disease cells. | 2008 Mar-Apr | Clin. Exp. Rheumatol. | pmid:18565252 |
| Kolar P et al. | Effects of celecoxib on the expression of osteoprotegerin, energy metabolism and cell viability in cultured human osteoblastic cells. | 2009 Jan-Feb | Clin. Exp. Rheumatol. | pmid:19327236 |
| Franke S et al. | Advanced glycation end products affect growth and function of osteoblasts. | 2011 Jul-Aug | Clin. Exp. Rheumatol. | pmid:21906430 |
| Pulsatelli L et al. | Circulating RANKL/OPG in polymyalgia rheumatica. | 2007 Jul-Aug | Clin. Exp. Rheumatol. | pmid:17888221 |
| Terpos E et al. | Early effects of IL-6 receptor inhibition on bone homeostasis: a pilot study in women with rheumatoid arthritis. | 2011 Nov-Dec | Clin. Exp. Rheumatol. | pmid:22032557 |
| Marco-Mingot M et al. | Lack of mutations in the RANK gene in Spanish patients with Paget disease of bone. | 2001 | Clin. Genet. | pmid:11531977 |
| Stolina M et al. | Regulatory effects of osteoprotegerin on cellular and humoral immune responses. | 2003 | Clin. Immunol. | pmid:14697750 |
| Graham LS et al. | Oxidized lipids enhance RANKL production by T lymphocytes: implications for lipid-induced bone loss. | 2009 | Clin. Immunol. | pmid:19699688 |
| Wang ST et al. | Increased plasma osteoprotegerin concentrations in Type 1 diabetes with albuminuria. | 2013 | Clin. Nephrol. | pmid:23073066 |
| Winther S et al. | Osteoprotegerin and mortality in hemodialysis patients with cardiovascular disease. | 2013 | Clin. Nephrol. | pmid:23547804 |
| Kagami S et al. | Osteoprotegerin affects the responsiveness of fibroblast growth factor-23 to high oral phosphate intake. | 2008 | Clin. Nephrol. | pmid:18826855 |
| Nishi H et al. | No change in circulating osteoprotegerin levels by intravenous calcitriol therapy among dialysis patients with secondary hyperparathyroidism. | 2006 | Clin. Nephrol. | pmid:16509469 |
| Koluman BU et al. | Association between osteoprotegerin, fetuin-A, carotid intima media thickness, and urinary albumin excretion in Type 2 diabetes. | 2013 | Clin. Nephrol. | pmid:23458176 |
| Kim HR et al. | Serum osteoprotegerin level is associated with degree of arteriovenous fistula stenosis in patients with hemodialysis. | 2013 | Clin. Nephrol. | pmid:24091316 |
| Kazama JJ et al. | Maxacalcitol therapy decreases circulating osteoprotegerin levels in dialysis patients with secondary hyperparathyroidism. | 2005 | Clin. Nephrol. | pmid:16047647 |
| Fahrleitner-Pammer A et al. | The effect of RANKL and OPG on bone mineral density in pre-dialysis chronic renal failure. | 2009 | Clin. Nephrol. | pmid:19473634 |
| Chaganti RK et al. | Elevation of serum tumor necrosis factor α in patients with periprosthetic osteolysis: a case-control study. | 2014 | Clin. Orthop. Relat. Res. | pmid:24307062 |
| Holt G et al. | The biology of aseptic osteolysis. | 2007 | Clin. Orthop. Relat. Res. | pmid:17620815 |
| Kanbe K et al. | Histological changes in bone marrow after treatment of infliximab for rheumatoid arthritis. | 2008 | Clin. Rheumatol. | pmid:18060342 |
| Chen CH et al. | Soluble receptor activator of nuclear factor-kappaB ligand (RANKL) and osteoprotegerin in ankylosing spondylitis: OPG is associated with poor physical mobility and reflects systemic inflammation. | 2010 | Clin. Rheumatol. | pmid:20690034 |
| Furuya T et al. | Associations between HLA-DRB1, RANK, RANKL, OPG, and IL-17 genotypes and disease severity phenotypes in Japanese patients with early rheumatoid arthritis. | 2007 | Clin. Rheumatol. | pmid:17876645 |
| Sarma PK et al. | Elevated serum receptor activator of NFkappaB ligand (RANKL), osteoprotegerin (OPG), matrix metalloproteinase (MMP)3, and ProMMP1 in patients with juvenile idiopathic arthritis. | 2008 | Clin. Rheumatol. | pmid:17703334 |
| Reveille JD | Biomarkers for diagnosis, monitoring of progression, and treatment responses in ankylosing spondylitis and axial spondyloarthritis. | 2015 | Clin. Rheumatol. | pmid:25939520 |
| Riesco M et al. | Osteoporosis in psoriatic arthritis: an assessment of densitometry and fragility fractures. | 2013 | Clin. Rheumatol. | pmid:23846386 |
| Yasunori K et al. | Reduction of urinary levels of pyridinoline and deoxypyridinoline and serum levels of soluble receptor activator of NF-kappaB ligand by etanercept in patients with rheumatoid arthritis. | 2008 | Clin. Rheumatol. | pmid:18338203 |
| Lories RJ and Luyten FP | Osteoprotegerin and osteoprotegerin-ligand balance: a new paradigm in bone metabolism providing new therapeutic targets. | 2001 | Clin. Rheumatol. | pmid:11254237 |
| Oelzner P et al. | Soluble receptor activator of NFkappa B-ligand and osteoprotegerin in rheumatoid arthritis - relationship with bone mineral density, disease activity and bone turnover. | 2007 | Clin. Rheumatol. | pmid:17541498 |
| Manganelli P et al. | OPG/RANKL system imbalance in a case of hepatitis C-associated osteosclerosis: the pathogenetic key? | 2005 | Clin. Rheumatol. | pmid:15583970 |
| Holen I and Shipman CM | Role of osteoprotegerin (OPG) in cancer. | 2006 | Clin. Sci. | pmid:16464170 |
| Daroszewska A and Ralston SH | Genetics of Paget's disease of bone. | 2005 | Clin. Sci. | pmid:16104845 |
| Crisafulli A et al. | Serum levels of osteoprotegerin and RANKL in patients with ST elevation acute myocardial infarction. | 2005 | Clin. Sci. | pmid:15926884 |
| Rhee EJ et al. | Relationship of serum osteoprotegerin levels with coronary artery disease severity, left ventricular hypertrophy and C-reactive protein. | 2005 | Clin. Sci. | pmid:15569000 |
| Dinçel E et al. | Hip fracture risk and different gene polymorphisms in the Turkish population. | 2008 | Clinics (Sao Paulo) | pmid:18925325 |
| Zhang Y et al. | Expression of leukocyte-associated immunoglobulin-like receptor-1 (LAIR-1) on osteoclasts and its potential role in rheumatoid arthritis. | 2013 | Clinics (Sao Paulo) | pmid:23778340 |
| Spirlandeli AL et al. | Hepatic Osteodystrophy: The Mechanism of Bone Loss in Hepatocellular Disease and the Effects of Pamidronate Treatment. | 2017 | Clinics (Sao Paulo) | pmid:28492723 |
| Kitamura K et al. | Zebrafish scales respond differently to in vitro dynamic and static acceleration: analysis of interaction between osteoblasts and osteoclasts. | 2013 | Comp. Biochem. Physiol., Part A Mol. Integr. Physiol. | pmid:23632157 |
| Maldonado S et al. | Mathematical modeling and analysis of force induced bone growth. | 2006 | Conf Proc IEEE Eng Med Biol Soc | pmid:17947010 |
| Wang Y et al. | Inhibitory effect of adenovirus-mediated siRNA-targeting BMPR-IB on UHMWPE-induced bone destruction in the murine air pouch model. | 2012 | Connect. Tissue Res. | pmid:22827452 |
| Pichler K et al. | Towards a better understanding of bone bridge formation in the growth plate - an immunohistochemical approach. | 2013 | Connect. Tissue Res. | pmid:23941205 |
| Sanuki R et al. | Compressive force induces osteoclast differentiation via prostaglandin E(2) production in MC3T3-E1 cells. | 2010 | Connect. Tissue Res. | pmid:20001844 |
| Lau CP et al. | Comparison of the anti-tumor effects of denosumab and zoledronic acid on the neoplastic stromal cells of giant cell tumor of bone. | 2013 | Connect. Tissue Res. | pmid:24060052 |
| Zhang F et al. | Compressive force stimulates the gene expression of IL-17s and their receptors in MC3T3-E1 cells. | 2010 | Connect. Tissue Res. | pmid:20497006 |
| Zhang YG et al. | Effect of negative pressure on human bone marrow mesenchymal stem cells in vitro. | 2010 | Connect. Tissue Res. | pmid:20067412 |
| Zhang PF et al. | Interrelationship of circulating matrix metalloproteinase-9, TNF-α, and OPG/RANK/RANKL systems in COPD patients with osteoporosis. | 2013 | COPD | pmid:23845033 |
| Løgstrup BB et al. | Microvascular dysfunction is associated with plasma osteoprotegerin levels in patients with acute myocardial infarction. | 2013 | Coron. Artery Dis. | pmid:23777975 |
| Hermann-Arnhof KM et al. | Initially elevated osteoprotegerin serum levels may predict a perioperative myocardial lesion in patients undergoing coronary artery bypass grafting. | 2006 | Crit. Care Med. | pmid:16374159 |
| Kobayashi Y et al. | Action of RANKL and OPG for osteoclastogenesis. | 2009 | Crit. Rev. Eukaryot. Gene Expr. | pmid:19191757 |
| Bengtsson AK and Ryan EJ | Immune function of the decoy receptor osteoprotegerin. | 2002 | Crit. Rev. Immunol. | pmid:12498383 |
| Ando K et al. | RANKL/RANK/OPG: key therapeutic target in bone oncology. | 2008 | Curr Drug Discov Technol | pmid:18690894 |
| Hjertner Ø et al. | Identification of new targets for therapy of osteolytic bone disease in multiple myeloma. | 2005 | Curr Drug Targets | pmid:16178802 |
| Ueland T et al. | TNF revisited: osteoprotegerin and TNF-related molecules in heart failure. | 2012 | Curr Heart Fail Rep | pmid:22453763 |
| López FJ | New approaches to the treatment of osteoporosis. | 2000 | Curr Opin Chem Biol | pmid:10959765 |
| Brown SA et al. | Local effects of malignancy on bone. | 2007 | Curr Opin Endocrinol Diabetes Obes | pmid:17982348 |
| Tankó LB | Effect of RANKL-specific denosumab on osteoclast number and function: a potential friend or foe? | 2007 | Curr Opin Investig Drugs | pmid:17907059 |
| Stankovic KM and McKenna MJ | Current research in otosclerosis. | 2006 | Curr Opin Otolaryngol Head Neck Surg | pmid:16974150 |
| De Leenheer E et al. | Evidence of a role for RANKL in the development of myeloma bone disease. | 2004 | Curr Opin Pharmacol | pmid:15251126 |
| Kostenuik PJ | Osteoprotegerin and RANKL regulate bone resorption, density, geometry and strength. | 2005 | Curr Opin Pharmacol | pmid:16188502 |
| Biskobing DM et al. | Novel therapeutic options for osteoporosis. | 2002 | Curr Opin Rheumatol | pmid:12118183 |
| Nakashima T et al. | RANKL and RANK as novel therapeutic targets for arthritis. | 2003 | Curr Opin Rheumatol | pmid:12707582 |
| Walsh NC and Gravallese EM | Bone loss in inflammatory arthritis: mechanisms and treatment strategies. | 2004 | Curr Opin Rheumatol | pmid:15201606 |
| Dougall WC | RANKL signaling in bone physiology and cancer. | 2007 | Curr Opin Support Palliat Care | pmid:18685382 |
| McClung MR | Inhibition of RANKL as a treatment for osteoporosis: preclinical and early clinical studies. | 2006 | Curr Osteoporos Rep | pmid:16527005 |
| Hamdy NA | Osteoprotegerin as a potential therapy for osteoporosis. | 2005 | Curr Osteoporos Rep | pmid:16303111 |
| Boyce BF and Xing L | The RANKL/RANK/OPG pathway. | 2007 | Curr Osteoporos Rep | pmid:17925190 |
| Honma M et al. | Regulatory mechanisms of RANKL presentation to osteoclast precursors. | 2014 | Curr Osteoporos Rep | pmid:24477414 |
| Bernstein CN | Inflammatory bowel diseases as secondary causes of osteoporosis. | 2006 | Curr Osteoporos Rep | pmid:16908001 |
| Schweikle E et al. | Osteoprotegerin positively regulates hematopoietic progenitor cells. | 2012 | Curr Stem Cell Res Ther | pmid:22023625 |
| Filvaroff E and Derynck R | Bone remodelling: a signalling system for osteoclast regulation. | 1998 | Curr. Biol. | pmid:9768352 |
| Hsu HC et al. | Tumor necrosis factor ligand-receptor superfamily and arthritis. | 2006 | Curr. Dir. Autoimmun. | pmid:16394654 |
| Sipos W et al. | Strategies for novel therapeutic approaches targeting cytokines and signaling pathways of osteoclasto- and osteoblastogenesis in the fight against immune-mediated bone and joint diseases. | 2008 | Curr. Med. Chem. | pmid:18220768 |
| Grigoropoulou P et al. | The role of the osteoprotegerin/RANKL/RANK system in diabetic vascular disease. | 2011 | Curr. Med. Chem. | pmid:21919846 |
| Alnaeeli M and Teng YT | Dendritic cells: a new player in osteoimmunology. | 2009 | Curr. Mol. Med. | pmid:19860668 |
| Sottnik JL and Keller ET | Understanding and targeting osteoclastic activity in prostate cancer bone metastases. | 2013 | Curr. Mol. Med. | pmid:23061677 |
| Blázquez-Medela AM et al. | Osteoprotegerin and diabetes-associated pathologies. | 2011 | Curr. Mol. Med. | pmid:21568931 |
| Secchiero P and Zauli G | Tumor-necrosis-factor-related apoptosis-inducing ligand and the regulation of hematopoiesis. | 2008 | Curr. Opin. Hematol. | pmid:18043245 |
| Kazama JJ | Osteoprotegerin and bone mineral metabolism in renal failure. | 2004 | Curr. Opin. Nephrol. Hypertens. | pmid:15199291 |
| Candido R | The osteoprotegerin/tumor necrosis factor related apoptosis-inducing ligand axis in the kidney. | 2014 | Curr. Opin. Nephrol. Hypertens. | pmid:24247823 |
| Kostenuik PJ and Shalhoub V | Osteoprotegerin: a physiological and pharmacological inhibitor of bone resorption. | 2001 | Curr. Pharm. Des. | pmid:11375772 |
| Buckle CH et al. | Targeting RANK/RANKL in the treatment of solid tumours and myeloma. | 2010 | Curr. Pharm. Des. | pmid:20166980 |
| Zhao B et al. | Characterization of synovial cell clones isolated from rheumatoid arthritis patients: possible involvement of TNF-alpha in reduction of osteoprotegerin in synovium. | 2008 | Cytokine | pmid:18083042 |
| Benatti BB et al. | Inflammatory and bone-related genes are modulated by aging in human periodontal ligament cells. | 2009 | Cytokine | pmid:19251432 |
| Sakata M et al. | Osteoprotegerin levels increased by interleukin-1beta in human periodontal ligament cells are suppressed through prostaglandin E(2) synthesized de novo. | 2002 | Cytokine | pmid:12126649 |
| Güncü GN et al. | Effect of inflammation on cytokine levels and bone remodelling markers in peri-implant sulcus fluid: a preliminary report. | 2012 | Cytokine | pmid:22592038 |
| Yaturu S et al. | Relationship of elevated osteoprotegerin with insulin resistance, CRP, and TNF-alpha levels in men with type 2 diabetes. | 2008 | Cytokine | pmid:18789716 |
| Heymann MF et al. | Role of the OPG/RANK/RANKL triad in calcifications of the atheromatous plaques: comparison between carotid and femoral beds. | 2012 | Cytokine | pmid:22402034 |
| Nanda KS et al. | Elevated circulating osteoprotegerin and reduced matrix-metalloprotease-9 in post-menopausal women with chronic Hepatitis C virus infection. | 2012 | Cytokine | pmid:22863720 |
| Harding G et al. | The effects of dexamethasone and dehydroepiandrosterone (DHEA) on cytokines and receptor expression in a human osteoblastic cell line: potential steroid-sparing role for DHEA. | 2006 | Cytokine | pmid:17161616 |
| Pantsulaia I et al. | Contribution of the familial and genetic factors on monocyte chemoattractant protein-1 variation in healthy human pedigrees. | 2005 | Cytokine | pmid:16213155 |
| Belibasakis GN et al. | The RANKL-OPG system is differentially regulated by supragingival and subgingival biofilm supernatants. | 2011 | Cytokine | pmid:21474331 |
| Rechenberg DK et al. | Periapical fluid RANKL and IL-8 are differentially regulated in pulpitis and apical periodontitis. | 2014 | Cytokine | pmid:25022970 |
| Yamada N et al. | Down-regulation of osteoprotegerin production in bone marrow macrophages by macrophage colony-stimulating factor. | 2005 | Cytokine | pmid:15996478 |
| Cannon JG et al. | Follicle-stimulating hormone promotes RANK expression on human monocytes. | 2011 | Cytokine | pmid:21159522 |
| Ramalho AC et al. | Effect of oestradiol on cytokine production in immortalized human marrow stromal cell lines. | 2001 | Cytokine | pmid:11792122 |
| Theoleyre S et al. | The molecular triad OPG/RANK/RANKL: involvement in the orchestration of pathophysiological bone remodeling. | 2004 | Cytokine Growth Factor Rev. | pmid:15561602 |
| Walsh MC and Choi Y | Biology of the TRANCE axis. | 2003 Jun-Aug | Cytokine Growth Factor Rev. | pmid:12787563 |